| 臺大學術典藏 |
2022-01-20T07:57:57Z |
Treatment outcomes of pediatric acute myeloid leukemia: a retrospective analysis from 1996 to 2019 in Taiwan
|
Yang Y.-L.; Jaing T.-H.; Chen S.-H.; Liu H.-C.; Hung I.-J.; Lin D.-T.; Yang C.-P.; Peng C.-T.; Lin K.-H.; Hsiao C.-C.; Jou S.-T.; Chen J.-S.; Lin M.-T.; Wang S.-C.; Chang T.-K.; Huang F.-L.; Cheng C.-N.; Wu K.-H.; Sheen J.-M.; Chen S.-H.; Lu M.-Y.; Hung G.-Y.; Yen H.-J.; Hsieh Y.-L.; Wang J.-L.; Chang Y.-H.; Chang H.-H.; Yeh T.-C.; Weng T.-F.; Hou J.-Y.; Chen B.-W.; Chen R.-L.; Wang L.-Y.; Ho W.-L.; Chen Y.-C.; Cheng S.-N.; Chao Y.-H.; Yang S.-H.; Huang T.-H.; SHU-WEI CHOU; Lin C.-Y.; Chen H.-Y.; Chao Y.-M.Y.; Liang D.-C.; Chang T.-T. |
| 臺大學術典藏 |
2016 |
Treatment outcomes of supraglottoplasty for pediatric obstructive sleep apnea: A meta-analysis
|
Lee, Chia-Fan;Hsu, Wei-Chung;Lee, Chia-Hsuan;Lin, Ming-Tzer;Kang, Kun-Tai; Lee, Chia-Fan; Hsu, Wei-Chung; Lee, Chia-Hsuan; Lin, Ming-Tzer; Kang, Kun-Tai; WEI-CHUNG HSU |
| 臺大學術典藏 |
2018-09-10T18:05:39Z |
Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation
|
Liang, J.-T. and Chen, T.-C. and Huang, J. and Jeng, Y.-M. and Cheng, J.C.-H.; YUNG-MING JENG |
| 臺大學術典藏 |
2019-11-18T08:17:49Z |
Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation
|
YUNG-MING JENG;Liang, Jin-Tung;Cheng, Jason Chia-Hsien;Huang, John;Chen, Tzu-Chun; Liang, Jin-Tung; Chen, Tzu-Chun; Huang, John; YUNG-MING JENG; Cheng, Jason Chia-Hsien |
| 臺大學術典藏 |
2020-03-06T08:24:53Z |
Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation
|
Liang J.-T.;Chen T.-C.;Huang J.;Yung-Ming Jeng;Cheng J.C.-H.; Liang J.-T.; Chen T.-C.; Huang J.; YUNG-MING JENG; Cheng J.C.-H. |
| 臺大學術典藏 |
2017 |
Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation
|
CHIA-HSIEN CHENG; Jeng Y.-M.; Huang J.; Chen T.-C.; Liang J.-T.; Liang J.-T.;Chen T.-C.;Huang J.;Jeng Y.-M.;Chia-Hsien Cheng |
| 臺大學術典藏 |
2021-05-03T02:20:52Z |
Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation
|
JIN-TUNG LIANG; Chen T.-C.; Huang J.; Jeng Y.-M.; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-03-02T14:00:05Z |
Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan
|
Liu, Yanfang; Tang, Chao Hsiun; Qiu, Hong; Siggins, Sarah; HSIN-AN HOU |
| 臺大學術典藏 |
2022-01-12T07:07:07Z |
Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan
|
Liu Y.; Tang C.-H.; Qiu H.; Siggins S.; HSIN-AN HOU |
| 國立成功大學 |
2024-12-31 |
Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan
|
Teng, Jerry;Chieh-Lin;Yeh;Su-Peng;Chen;Tsai-Yun;Hung;Yu-Chin;Lin;Yun-Chu;Li;Syue, Sin;Wang;Ming-Chung;Huang;Shang-Yi |
